Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Baley Smith

Nurse Practitioner, Primary Care Laurel, MS Nurse Practitioner

NPI 1952009805 CMS profile 11503488

5135 Highway 84 W, Laurel, MS 39443

Open in the dashboard

General payments

$313

11 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Baley Smith of Laurel, MS is reported in the CMS Open Payments database as having received $313 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $279 9
2023 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Baley Smith
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Baley Smith were reported at $279. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Baley Smith Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $34 $163 $53–$481 $160
2024 $0 $176 $54–$511 $164
2025 $279 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $138 4 payments
  2. Novo Nordisk Inc $119 4 payments
  3. Lilly USA, LLC $41 2 payments
  4. GlaxoSmithKline, LLC. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $313 11 payments
Products named General payments · program years 2023–2025
  1. AIRSUPRA $71 1 payment
  2. FARXIGA $67 3 payments
  3. Wegovy $65 1 payment
  4. RYBELSUS $54 3 payments
  5. ZEPBOUND $41 2 payments
  6. MOUNJARO $23 1 payment
  7. Ozempic $20 1 payment
  8. AREXVY $14 1 payment
  9. SHINGRIX $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,138

Median for Nurse Practitioner: 389

Drug cost

$78,260

Median for Nurse Practitioner: $21,885

Branded share of claims

22.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 34 $27,169
Ozempic Semaglutide Brand 15 $18,828
Eliquis Apixaban Brand 18 $12,459
Albuterol Sulfate Hfa Albuterol Sulfate Brand 36 $1,250
Ventolin Hfa Albuterol Sulfate Brand 18 $1,169
Gabapentin Generic 98 $1,102
Metoprolol Succinate Generic 45 $735
Omeprazole Generic 68 $659
Amlodipine Besylate Generic 119 $617
Levothyroxine Sodium Generic 75 $613

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$11,629

Of which drugs: $311

Medicare patients

161

Average age 73

Services billed

844

88 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 38%
Ischemic heart disease 30%
Depression 19%
Chronic kidney disease 17%
Atrial fibrillation 16%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 16 44 $112
Injection, ceftriaxone sodium, per 250 mg J0696 Office 48 214 $55
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 20 58 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record